Astrocytes in the striatum appear to play a critical role in stuttering. Researchers found treatment with risperidone helped reduce stuttering by increasing the metabolism of striatal astrocytes.
Study reveals the role the Gao protein plays in a rare genetic movement disorder often diagnosed during infancy and early childhood.
The decline of striosomal activity in the brain may explain why people lose the motivation to learn as they age.
Researchers recorded alterations in levels of both dopamine and serotonin in the brain when people perform perception and decision making based tasks.
The striatum and premotor cortex show altered patterns in neural activity when encoding time. The dynamics of the striatum were more sequential than those of the premotor cortex.
Researchers found specific neurons in the striosome that help mice learn to avoid negative experiences.
Study reports the putamen, not just the cortex, contributes to the brain's ability to multitask.
Dopamine receptors have different molecular features and functions depending on their anatomical location within the striatum. The findings could help develop better-targeted treatments for a range of disorders from schizophrenia to Parkinson's disease.
Involuntary movements and tremors caused as a result of taking dopamine replacement medications for Parkinson's disease can be alleviated through the suppression of RasGRP1.
Neuroimaging reveals how dopamine released from the striatum influences brain activity in the motor cortex and insular.
During memory tasks, people with psychosis have different patterns of activity in the prefrontal and mediotemporal brain areas compared to those without the disorder. When exposed to cannabidiol (CBD), the activity of the brain areas became more like those seen in the controls for people with psychosis. Patients reported a decrease in symptoms of psychosis following one dose of CBD. Researchers stress that no definitive conclusions could be made about the effectiveness of CBD use over a sustained period.
10% of patients diagnosed with Parkinson's disease are between the ages of 21 and 50. For those with young-onset Parkinson's disease, researchers report the foundations for the disease may have been apparent before they were born. The study also points to a drug, currently approved to treat precancerous skin growths, that has the potential to reduce elevated levels of alpha-synuclein.
